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Platelets and Scleroderma 
Patients with progressive systemic sclerosis, or scleroderma, have 
a defect ive immune system. For this reason, many investigators 
have focused on lymphocytes and monocytes in their search to 
underst:lI1d this disease. But the first manifestation of scleroderma 
frequently is Raynaud 's phenomenon; and so it is possible, ac-
cording to Vincent Fa langa of the University of Miami School 
of Medicine, that scleroderma might actuall y be caused by a de-
fective platelet function . In this issue, Falanga and Susan T iegs, 
Stephanie Alstadt of the University of Pittsburgh School of Med-
icine, and Anita Roberts and Michael Sporn of the National Can-
cer Institute report evidence supporting the hypothesis that de-
fective platelct function induces scleroderma. 
Esscntia l to understanding scleroderma is the determination of 
why the fibrob las ts from patients' sk in and internal organs make 
increased amounts of collagen and other matrix proteins. Because 
paticnts havc antinucl ea r antibodies and other immune system 
abnormalities, it has been suggested that perhaps lymphocytes or 
monocytes releasc growth mediators that stimulate collagen syn-
th esis. Yet, says Falanga, "platelets also normally release many 
substances that are important for connective tissue formation." 
And 90% of scleroderma patients have Raynaud's phenomenon , 
in which platelets increase their secretion of growth factors and 
other substances. 
To tcst their platelet hypothesis, Falanga and his colleagues first 
used ADP to release platelet substances. T hen they tested this 
platclet extract in vitro and found that fibroblasts from sclero-
derma patients responded abnormall y to it. For example, the 
scleroderma fibrob lasts increased thcir synthesis of glycosami-
nogens to a greater exten t than do normal fibroblasts. This was 
significant, the investigators felt, because glycosaminogens ac-
cumulate in the dermis in the elderly and acti ve phases of sclero-
derma. "We feel that glycosaminogens arc close to the first patho-
genic response," Falanga says. 
Thc next step was to test purified growth factors that are re-
leased by platelets. Falanga and his associates decided to test trans-
forming growth factor-beta, which plays a key role in connective 
tissue formation and which is present in 500 times greater quan-
tities in platelets than in other tissues. They found that there is a 
selective incre'ase in glycosaminogen synthesis by fibroblasts from 
scleroderma patients as compared to normal fibroblasts w hen thc 
cells are exposed to transforming growth factor-beta. 
Since transforming growth factor-beta is present in all celis, 
incl udin g lymphocytes, the invcstigators do not want to rule out 
the possibility that immune system cells contribute to the path-
ogenesis ofsclcroderma. But, says Falanga, if their defective plate-
let hypothesis is correct, it may be worthwhile for the treatment 
of sclcroderma to concentrate on developing drugs that inhibit 
specific platelet function. "The treatment so far is stopping col-
lagen synthesis. It acts right at the end of the diseas~ where col-
lagen is already present. There is no currentl y accepted therapy 
to stop collagen deposition," he says . 
Isotretinoin Has Anti-Inflammatory Effects 
Patients with severe, recalcitrant cystic acne who are treated with 
isotrctinoin frequcntly have red uccd inflammation in their lesions. 
David N orris, Roberta Osborn, Wi lliam Robinson, and Marcia 
Tonnesen, of the University of Colorado School of Medicine in 
Denver, thercforc asked w hether isotrctinoin might itself have 
anti- inflammatory effects in addition to its other well-known ef-
fects. They report in this issue that thc drug has profound anti-
inflammatory effects in vivo and suggest that isotretionin might 
be uscful as an anti- inflammatory agent in other diseases. 
Thc group stud ied a group of 7 cysti c acne patients who were 
recciving isotretinoin and looked at whether their neutrophils and 
monocytes respond normally to chemotactic stimuli in vivo. T he 
chcmoattractant used was the patients' own activated serum. "To 
our surp rise, thcrc was a 98% inhibition of the celis' chemotactic 
responsc to activated serum in patients taking iso tretinoin," says 
Norris. Isotrctinoin, thus had a "a tremendous anti-inflammatory 
cffcct in vivo . We think this is biologicall y relevant," N orris 
remarks. In contrast, he says, hi s group had found previous ly 
that w hcn acnc patients took very high doscs of steroids, thc 
chcmotact ic rcsponse of ncutrophils and monocy tes to their own 
activatcd serum was inhibitcd on ly 50%. 
Ncxt, Norris and his colleagues attempted to discovcr the 
mechan isms for this anti-flammatory effct of isotretinoin. They 
succeeded in excluding two hypotheses. First, they considered 
the possibi lity that the serum of patients receiving isotretinoin is 
not able to be activated to produce chemoa ttractants. Th is is not 
the case. T hey report. 
N ext, N orris and his coll eagues asked whether the normal in 
vitro assay for chemotaxis-the ability of cells to response across 
filters-was inhibited by isotretinoin. It was not, indicating, N or-
ris says, that "probably the effect we see in vivo is an effect on 
leukocyte migration across biological barriers." 
Norris postulates that the reason isotretinoin has anti-inflam-
matory effects in vivo but not in vitro is that cells often have to 
secrete proteases to get through biological barriers, such the ep-
ithelium alld epidermal cells. This may be relevant since others 
have shown that retinoids inhibit protease release indirectl y in 
vivo and directly in vitro. 
T he clinical application of these findings, N orris says, is that 
"isotretinoin may be effective in decreasing or moderating other 
types of neutrophil-mediated tissue damage." For example, the 
drug may prove useful in treating patients with neu trophilic der-
matoses or bullous pemphigoid. " What we need are controlled 
studies to test this possibility, and we also may need to use iso-
tretinoin in combination with other anti-inflammatory drugs," 
Norris concludes. 
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Why People Get Sick After a Bad Sunburn 
In this iss ue, a group of resea rchers from the Portland Veterans 
Admini strati on Medical Center and the NIH provide an ex pla-
nation for the chills and fever that frequently fo llow sunburn . 
John Ansel, Thom as Luger, and Ira Green suggest that the sun-
burn-induced fever is due to the release of interleukin-l by ke-
ratinocytes. 
Interl eukin-l, or IL-l , is secreted by a variety of cell types, 
including monocytes and keratinocytes, and it affects a number 
of immune responses. For example, it activates T and B cells and 
induces these cells to differentiate. In addition, it causes fever. 
Because IL-l is secreted by keratinocytes when they are exposed 
to ultraviolet li ght, Ansel and his colleagues asked whether this 
substance could raise the body temperature of rabbits that were 
UV irradiated. They found that sta rtin g 2 hours after irradiation, 
the rabbits' body temperature rose. T he feve r peaked at 4 to S 
hours after irradiation and then returned to normal. T his fever 
corresponded to an increase in serum IL-l . When the investigato rs 
gave serum from the irradiated rabbits to rabbits that were not 
irradiated, the recipi ent rabbits developed fevers. 
Patients with autoimmune diseases may be particularl y sus-
ceptible to the fever-indu cing effects of sunlight, Ansel reports. 
As many as 40% of patients with systemic lupus erythematos us 
(SLE), for example, develop symptoms w hen they go into the 
sunlight. It is also possible, according to Ansel, that ultraviolet 
light causes the release of IL-l or other cytokines that induce or 
exacerbate autoimmune-mediated dama ge in SLE and related dis-
eases of photosensitivity . 
Unders tanding Steroids and Acne and Alopecia 
N earl y 20 years ago, it was proposed that an ac ti ve androgenic 
molecule, Sa-steroid reductase, is made in increased amounts in 
the skin of acne patients and on the heads of patients w ith an-
drogenetic alopecia. This increased local production of the an-
drogenic substances, according to the prevailing hypothesis, causes 
the two common disorders . 
But Andre Dijkstra and C. M . A. A. Goos of the Univers ity 
of Nijmegen in the N etherlands, William C unliffe and C harles 
Sultan of the General Infirmary at Leeds in England , and Alphons 
J. M . Vermorken of INSERM in M ontpellicr, France, report in 
this issue that the hypothesis may be incorrect. The increased 
amount of Sa-steroid redu ctase in the skin may be a secondary 
effect of acne and androgenetic alopecia rather than a primary 
one. Their results, however, suggest a new rationale for treatment 
of these disorders. 
The old hypothesis, says Vermorken , arose because resea rchers 
noted that acne and androgenetic alo pecia are androgen depen-
dent. Moreover, the mechanism of action of androgens in the 
skin is th ought to be like their mechanisms of ac tion in the pros-
tate. In the prostate, the enzyme Sa-steroid reductase converts 
testosterone to Sa-dihydrotestosterone. So, says Vermorken, in-
vestigators reasoned that " perh aps the local fo rm ation of Sa-
steroid reductase in the skin is important. They took samples 
fro m skin of acne patients and of patients with androgenic alopecia 
and found that there was an increase in the amount of Sa-steroid 
reductase. " 
Vermorkcn and his associa tes decided to try and veri fy the 
hypo thesis by meas uring Sa-steroid reductase in purifi ed oxi-
olated skin sa mpler. They looked at Sa-steroid reductase activity 
in different layers of the same skin biopsy, thereby comparing 
this enzy me's activity in epidermis, dermis, sebaceous glands, 
and sweat glands . 
What they found, Vermorken says, is that " most of the enzy me 
activity of the skin was localized in the sebaceous glands. But the 
sebaceous gland sizes are increased in both diseases." For that 
reason, he and his colleagues suggc'st, the increased amou nt of 
Sa-steroid reductase in acne and androgenetic alopecia may be a 
secondary effect of larger sebaceous glands rather than a primary 
cause of these two diseases. 
N onetheless , the result also indica tes that if the sizes of the 
sebaceous glands of patients with acne and alopecia could be 
diminished, their local production of Sa-steroid redu ctase could 
go down and their disease might be amelio rated. The drug 13-
cis retinoic acid red uces sebaceous gland size, but Vermorken says 
he has had neither the time nor the money to study whether this 
drug also reduces Sa-steroid reductase activity in sebaceous glands. 
N onetheless, these results sugges t that any agent that decreases 
the size of the sebaceous gland would decrease the amount of Sa-
steroid reductase and thereby improve androgen-dependent dis-
orders such as acne. Since 13-cis retinoic acid improves acne and 
reduces sebaceous gland size, Sa-steroid reductase ac tivity is pre-
sumably decreased by the agent, but Vermoken has not had the 
time or money to confi rm this effect. 
